Acumen Pharmaceuticals (ABOS) vs Codexis (CDXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Codexis (CDXS) over the past year, gaining 11.7% versus a loss of 44.9%. Over five years, ABOS leads with a -84.5% price change compared with -95.0% for CDXS. Codexis is the larger company by market cap ($154.4 million vs $151.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | CDXS |
|---|---|---|
| Share price | $2.10 | $1.41 |
| Market cap | $151.87M | $154.40M |
| 1-day change | +3.45% | +3.68% |
| YTD return | -0.47% | -13.50% |
| 1-year return | +11.70% | -44.92% |
| 5-year return | -84.50% | -95.02% |
| EPS (TTM) | $-1.64 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $2.98 |
| 52-week low | $1.50 | $0.96 |
| Distance from 52-week high | -41.67% | -52.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +261.90% | +335.46% |
| Average volume | 432.46K | 1.10M |
| Shares outstanding | 72.32M | 109.51M |
| Employees | 60 | 146 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed CDXS by 56.6 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Healthcare · Biotechnology · 60 employees
About Codexis
CDXS stock →Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Healthcare · Biotechnology · 146 employees
ABOS vs CDXS FAQ
Which is bigger, Acumen Pharmaceuticals or Codexis?
Codexis (CDXS) is larger, with a market capitalization of $154.40M compared with $151.87M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or CDXS?
ABOS returned +11.70% over the past 12 months, compared with -44.92% for CDXS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Codexis in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.